199 related articles for article (PubMed ID: 36074313)
1. CD25-targeted antibody-drug conjugate camidanlumab tesirine for relapsed or refractory classical Hodgkin lymphoma.
Xu B; Li S; Kang B; Fan S; He Z; Zhou J
Invest New Drugs; 2022 Dec; 40(6):1333-1341. PubMed ID: 36074313
[TBL] [Abstract][Full Text] [Related]
2. A New Target for Hodgkin Lymphoma - Camidanlumab Tesirine.
Epperla N; Hamadani M
Curr Hematol Malig Rep; 2021 Feb; 16(1):19-24. PubMed ID: 33492560
[TBL] [Abstract][Full Text] [Related]
3. Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study.
Hamadani M; Collins GP; Caimi PF; Samaniego F; Spira A; Davies A; Radford J; Menne T; Karnad A; Zain JM; Fields P; Havenith K; Cruz HG; He S; Boni J; Feingold J; Wuerthner J; Horwitz S
Lancet Haematol; 2021 Jun; 8(6):e433-e445. PubMed ID: 34048682
[TBL] [Abstract][Full Text] [Related]
4. Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study.
Goldberg AD; Atallah E; Rizzieri D; Walter RB; Chung KY; Spira A; Stock W; Tallman MS; Cruz HG; Boni J; Havenith KEG; Chao G; Feingold JM; Wuerthner J; Solh M
Leuk Res; 2020 Aug; 95():106385. PubMed ID: 32521310
[TBL] [Abstract][Full Text] [Related]
5. Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma.
Xu B
Eur J Clin Pharmacol; 2022 May; 78(5):707-719. PubMed ID: 35061047
[TBL] [Abstract][Full Text] [Related]
6. Exposure-response analysis of Camidanlumab tesirine in patients with relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma.
Toukam M; Boni JP; Hamadani M; Caimi PF; Cruz HG; Wuerthner J
Cancer Chemother Pharmacol; 2023 Jan; 91(1):1-12. PubMed ID: 36333463
[TBL] [Abstract][Full Text] [Related]
7. A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.
Kahl BS; Hamadani M; Radford J; Carlo-Stella C; Caimi P; Reid E; Feingold JM; Ardeshna KM; Solh M; Heffner LT; Ungar D; He S; Boni J; Havenith K; O'Connor OA
Clin Cancer Res; 2019 Dec; 25(23):6986-6994. PubMed ID: 31685491
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics analysis of camidanlumab tesirine in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma.
Toukam M; Wuerthner J; Havenith K; Hamadani M; Caimi PF; Kopotsha T; Cruz HG; Boni JP
Cancer Chemother Pharmacol; 2023 Jan; 91(1):13-24. PubMed ID: 36333464
[TBL] [Abstract][Full Text] [Related]
9. Future directions in Hodgkin lymphoma: checkpoint inhibitors and beyond.
Desai S; Ansell SM
Leuk Lymphoma; 2021 Aug; 62(8):1795-1804. PubMed ID: 33602008
[TBL] [Abstract][Full Text] [Related]
10. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.
Caimi PF; Ai W; Alderuccio JP; Ardeshna KM; Hamadani M; Hess B; Kahl BS; Radford J; Solh M; Stathis A; Zinzani PL; Havenith K; Feingold J; He S; Qin Y; Ungar D; Zhang X; Carlo-Stella C
Lancet Oncol; 2021 Jun; 22(6):790-800. PubMed ID: 33989558
[TBL] [Abstract][Full Text] [Related]
11. The optimal management of relapsed and refractory Hodgkin lymphoma: post-brentuximab and checkpoint inhibitor failure.
Grover NS; Dittus C; Thakkar A; Beaven AW
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):510-518. PubMed ID: 38066906
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for Hodgkin lymphoma: From monoclonal antibodies to chimeric antigen receptor T-cell therapy.
Maaroufi M
Crit Rev Oncol Hematol; 2023 Feb; 182():103923. PubMed ID: 36702422
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL;
Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562
[TBL] [Abstract][Full Text] [Related]
14. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.
Younes A; Gopal AK; Smith SE; Ansell SM; Rosenblatt JD; Savage KJ; Ramchandren R; Bartlett NL; Cheson BD; de Vos S; Forero-Torres A; Moskowitz CH; Connors JM; Engert A; Larsen EK; Kennedy DA; Sievers EL; Chen R
J Clin Oncol; 2012 Jun; 30(18):2183-9. PubMed ID: 22454421
[TBL] [Abstract][Full Text] [Related]
15. CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity.
Zammarchi F; Havenith K; Bertelli F; Vijayakrishnan B; Chivers S; van Berkel PH
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32912922
[TBL] [Abstract][Full Text] [Related]
16. Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma.
Hamadani M; Radford J; Carlo-Stella C; Caimi PF; Reid E; O'Connor OA; Feingold JM; Ardeshna KM; Townsend W; Solh M; Heffner LT; Ungar D; Wang L; Boni J; Havenith K; Qin Y; Kahl BS
Blood; 2021 May; 137(19):2634-2645. PubMed ID: 33211842
[TBL] [Abstract][Full Text] [Related]
17. Where does brentuximab vedotin fit into the management of patients with Hodgkin lymphoma?
Goyal SD; Bartlett NL
Curr Hematol Malig Rep; 2012 Sep; 7(3):179-85. PubMed ID: 22669711
[TBL] [Abstract][Full Text] [Related]
18. Development of recalcitrant cutaneous eruptions in patients with relapsed/refractory Hodgkin's lymphoma undergoing treatment with camidanlumab tesirine.
Himed S; Chung C; Dulmage B; Jaglowski S; Bond D; Maddocks K; Kaffenberger BH
J Eur Acad Dermatol Venereol; 2023 Jul; 37(7):e890-e893. PubMed ID: 36800311
[No Abstract] [Full Text] [Related]
19. Management of relapsed or refractory hodgkin lymphoma with second-generation antibody-drug conjugates: focus on brentuximab vedotin.
Mei M; Thomas S; Chen R
BioDrugs; 2014 Jun; 28(3):245-51. PubMed ID: 24258497
[TBL] [Abstract][Full Text] [Related]
20. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]